Literature DB >> 32721951

Growth Rate of Geographic Atrophy Secondary to Age-related Macular Degeneration: A Meta-analysis of Natural History Studies and Implications for Designing Future Trials.

Jianyong Wang, Gui-Shuang Ying.   

Abstract

INTRODUCTION: There is no effective treatment for geographic atrophy (GA). To help design future GA treatment trials, we conducted a meta-analysis for GA growth rate and its variability in natural history studies.
METHODS: Literatures were searched up to April 30, 2020. Data were extracted independently by 2 authors and analyzed using random-effects models.
RESULTS: The pooled mean GA growth rate was 1.66 mm2/year (SD=1.27 mm2/year, I2=97.0%, p<0.001) from 23 studies (3078 patients) reported with growth rate in mm2/year and 0.33 mm/year (SD=0.17 mm/year, I2=83.0%, p<0.001) from 12 studies (1808 patients) reported with growth rate in mm/year. Larger mean baseline GA area in mm2 was associated with larger mean growth rate in both mm2/year and mm/year (p<0.001). The sample size at 85% power for detecting 15% reduction in growth rate in a two-arm GA trial is 464 and 209 patients per arm respectively for using mm2/year and mm/year as the primary outcome. DISCUSSION/
CONCLUSION: GA natural history studies had pooled mean (SD) GA growth rate of 1.66 (1.27) mm2/year or 0.33 (0.17) mm/year. Because GA growth rate using mm/year requires smaller sample size than using mm2/year, GA growth rate in mm/year is recommended as the primary outcome measure for future GA trials.
© 2020 S. Karger AG, Basel.

Entities:  

Year:  2020        PMID: 32721951     DOI: 10.1159/000510507

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  4 in total

Review 1.  Perspectives from clinical trials: is geographic atrophy one disease?

Authors:  Sobha Sivaprasad; Shruti Chandra; Jeha Kwon; Noorulain Khalid; Victor Chong
Journal:  Eye (Lond)       Date:  2022-05-31       Impact factor: 3.775

2.  Personalized Atrophy Risk Mapping in Age-Related Macular Degeneration.

Authors:  Anthony Gigon; Agata Mosinska; Andrea Montesel; Yasmine Derradji; Stefanos Apostolopoulos; Carlos Ciller; Sandro De Zanet; Irmela Mantel
Journal:  Transl Vis Sci Technol       Date:  2021-11-01       Impact factor: 3.283

3.  A hierarchical Bayesian entry time realignment method to study the long-term natural history of diseases.

Authors:  Liangbo L Shen; Lucian V Del Priore; Joshua L Warren
Journal:  Sci Rep       Date:  2022-03-22       Impact factor: 4.996

4.  Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy.

Authors:  Thomas Hong; Andrew Chang; Ted Maddess; Jan Provis; Philip Penfold
Journal:  BMJ Open Ophthalmol       Date:  2022-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.